Citation

Johnson BA. Alcohol Clin. Exp. Res. 2017; 41(4): 703-707.

Affiliation

University of Maryland School of Medicine, 110 South Paca Street, Baltimore, MD, 21201.

Copyright

(Copyright © 2017, John Wiley and Sons)

DOI

10.1111/acer.13341

PMID

28118502

Abstract

This interesting paper by Witkiewitz and colleagues (Witkiewitz et al. 2017) calls for the need to create a more comprehensive scale to acknowledge and measure the naturally fluctuating levels of drinking among patients. As such, there is a dire need to unify, under a common instrument, a clinically meaningful endpoint measure to determine the efficacy of treatment for alcohol use disorder (AUD) for both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Such a homology would have the advantage that any treatment found efficacious in either of these influential and pioneering domains would be applicable to the other. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Language: en